Lauren E. Colbert, MD MSCR

physician-scientist, GYN brachytherapist @mdandersonnews. #biostats nerd. we study tumor and vaginal #Microbiome, #HPV. Proud girl mom.

[Lauren E. Colbert, MD MSCR @colbertle]

1/ 🔬🧫Tumoral lactic acid bacteria can rewire tumor metabolism and drive cancer treatment response. Our @cancercell paper is finally out #openaccess online! 🦠🔬
https://t.co/N85xQegPbt

[Lauren E. Colbert, MD MSCR @colbertle]

@DrMariSea @RRS_RadRes @ACKoongMDPhD 😆 Colbert Lab will be there! @DalissaNF already put together a mandatory abstract workshop to make sure everyone submits

[Lauren E. Colbert, MD MSCR @colbertle]

New policy: only attending conferences in places where you need to match your sun hat to your suit. #tmcs2024

[Allison (Allie) Judge @catalliesys]

Do you want to use patient-derived organoids to model cervical cancer? Our group (study led by staff scientist Rui Wang!) did the hard troubleshooting for you and published it as an easy-to-follow protocol 🤗
https://t.co/RQyvoo0bZY

[Lauren E. Colbert, MD MSCR @colbertle]

Whoever gets to work with @goharmanzar will be one lucky person!! 🍀 She is a one of a kind scientist, teacher and mentor! #postdocjobs #Postdocs

[Lauren E. Colbert, MD MSCR @colbertle]

@StephDudzinski @MDAndersonNews @sumeethj You’re clearly doing a great job, Mama! ☺️

[Lauren E. Colbert, MD MSCR @colbertle]

Look at those RT waterfall plots 🤩 Great work by @AnnKloppMD and @adam_grippin !!

[Ramez Kouzy, MD @RKouzyMD]

Proud of my co-resident @adam_grippin for presenting the IMMUNOCERV Phase II Trial results at #ASTRO24! Exciting insights on how PDS0101 vaccine w/ CRT could contribute to the care of patients with advanced cervical cancer. @AnnKloppMD @colbertle @ChelseaPinnix @MDAndersonNews

[Steven H. Lin @StevenLin_MDPhD]

Remarkable innovation by another stellar resident @MDAndersonNews @BenjaminSchrank in @wenjiang_nano lab to enhance anti-tumor immunity through a novel macrophage targeting ADC!! @ACKoongMDPhD @ChelseaPinnix

[Chelsea C Pinnix MD PhD @ChelseaPinnix]

Brilliant presentation by @MDAndersonNews #RadOnc PGY5 resident @BenjaminSchrank today. This is the FIRST antibody-drug conjugate specifically designed to enhance immune activation against cancer. LET’S GOOOO! @wenjiang_nano @BettyKimLab @ACKoongMDPhD #ASTRO24

[Betty Y.S. Kim, MD, PhD, FRCSC, FAIMBE @BettyKimLab]

@MDAndersonNews @BenjaminSchrank @BenjaminSchrank is without a doubt one of the very best physician scientist trainee I have ever encountered. Quadruple threat: great scientist, leadership skills, gifted educator and super kind/humble. Truly exceptional. He’s also on the job market. So proud!

[UT MD Anderson @UTMDAnderson]

Dr. Benjamin Schrank explains his recent research on a first-in-class antibody-drug conjugate that is designed to trigger an immune response, as a complementary strategy to radiation therapy.

Read more: https://t.co/hS5d9zkV3W @BenjaminSchrank #ASTRO24 #EndCancer

[Lauren E. Colbert, MD MSCR @colbertle]

@pipcosper

[Stephanie Dudzinski MD, PhD @StephDudzinski]

⭐️PGY3 @dr_p_carriere @MDAndersonNews #radonc co-resident crushed his talk on pt-reported functional decline post-AS, RP, EBRT w/o ADT, or LDR at #ASTRO2024 @ASTRO_org

Great job, Patrick!!! 👏👏👏

& Excellent mentorship from @KHoffmanMD 💪

[Lauren E. Colbert, MD MSCR @colbertle]

Fantastic work by one of our PGY5 aspiring physician scientists! @Vince_BernPag is the real deal and a total phys sci superstar - it’s amazing to see this project develop from the beginning to these great discoveries and looking forward to how his work will impact patients

[Chelsea C Pinnix MD PhD @ChelseaPinnix]

Congrats to @MDAndersonNews #RadOnc PGY5 Holman pathway resident @Vince_BernPag on this compelling work exploring molecular processes related to response to RT via longitudinal tumor biopsies for pts with pancreatic cancer before & after SBRT.@ACKoongMDPhD @PrajnanDasMD #ASTRO24

[Albert Koong, MD PhD @ACKoongMDPhD]

Persister cells after neoadjuvant treatment for pancreatic cancer are enriched in genes involved in #ferroptosis and #cuproptosis. Fantastic translational study by ⁦@Vince_BernPag⁩ from ⁦@MDAndersonNews⁩. #ASTRO24 #endcancer #radonc

[Lauren E. Colbert, MD MSCR @colbertle]

Come hang out with us at 11! @AnnKloppMD

[UT MD Anderson @UTMDAnderson]

What's new in enhancing gynecologic outcomes?

Meet our experts, Drs. Lauren Colbert and Ann Klopp, in booth 741 to learn more at 11 a.m. EDT. @colbertle @AnnKloppMD (3/4) #ASTRO24 #EndCancer

[UT MD Anderson @UTMDAnderson]

What's new in enhancing gynecologic outcomes?

Meet our experts, Drs. Lauren Colbert and Ann Klopp, in booth 741 to learn more at 11 a.m. EDT. @colbertle @AnnKloppMD (3/4) #ASTRO24 #EndCancer

[Lauren E. Colbert, MD MSCR @colbertle]

@BettyKimLab

[UT MD Anderson @UTMDAnderson]

A first-in-class antibody-drug conjugate works by targeting protein CD47, which helps immune cells activate and engulf cancer cells. The drug triggers an adaptive immune response to help eliminate the tumor. Learn more about the research, which Dr. Ben Schrank will present at #ASTRO24: https://t.co/DMMFiG9878 #EndCancer

[Lauren E. Colbert, MD MSCR @colbertle]

Way to go @dr_p_carriere!

[Urology Times @UrologyTimes]

1 in 3 men to receive RP or EBRT for treatment of localized #ProstateCancer reported “moderate to big problems” with sexual function 10 years later, according to a new longterm study at #ASTRO24.

Read more longterm functional outcomes from #CEASAR here: https://t.co/FXK8qppgv0